Concepedia

Author

VM Santana

St. Jude Children's Research Hospital

Also Known As

V Santana, V.A.R. Sant’Ana, VM Santana, de Santana, Vagner Figueiredo

14

Publications

851

Citations

9

H-Index

5

Concepts

All Affiliations

St. Jude Children's Research Hospital
VS

About

VM Santana is an author at St. Jude Children's Research Hospital specializing in hematology, oncology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

33

2

Pharmacology

1

1

33

3

Hematology

1

1

33

4

Oncology

1

1

33

5

Pharmacotherapy

1

1

33

VM Santana

×

9

Publications

847

Citations

9

H-Index

YearCitations

Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells

DR Rill, VM Santana, WM Roberts,

Blood

1994

409

Clinicopathologic features and treatment outcome of children with large- cell lymphoma and the t(2;5)(p23;q35)

J T Sandlund, CH Pui, WM Roberts,

Blood

1994

108

Pharmacokinetics of subcutaneous recombinant human granulocyte colony- stimulating factor in children

Norbert Stute, VM Santana, JH Rodman,

Blood

1992

88

Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation

TJ Moss, Mitchell S. Cairo, VM Santana,

Blood

1994

81

Pharmacokinetics of subcutaneous recombinant human granulocyte colony- stimulating factor in children

Norbert Stute, VM Santana, JH Rodman,

Blood

1992

69

Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects

MK Arnaout, KM Radomski, Xin Tong,

Leukemia

2000

33

Two karyotypically independent leukemic clones with the t(8;21) and 11q23 translocation in acute myeloblastic leukemia at relapse [published erratum appears in Blood 1989 Aug 15;74(3):1180]

Y Hayashi, SC Raimondi, FG Behm,

Blood

1989

23

Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells

DR Rill, VM Santana, WM Roberts,

Blood

1994

19

XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.

María Koehler, CA Hurwitz, Robert A. Krance,

PubMed

1994

17

Page 1